Is there any correlation among MKK4 (mitogen-activated protein kinase kinase 4) expression, clinicopathological features, and KRAS/NRAS mutation in colorectal cancer. (2nd August 2020)
- Record Type:
- Journal Article
- Title:
- Is there any correlation among MKK4 (mitogen-activated protein kinase kinase 4) expression, clinicopathological features, and KRAS/NRAS mutation in colorectal cancer. (2nd August 2020)
- Main Title:
- Is there any correlation among MKK4 (mitogen-activated protein kinase kinase 4) expression, clinicopathological features, and KRAS/NRAS mutation in colorectal cancer
- Authors:
- Dogan, Mutlu
Guresci, Servet
Acikgoz, Yusuf
Ergun, Yakup
Kos, Fahriye Tugba
Bozdogan, Onder
Bal, Oznur - Abstract:
- ABSTRACT: Background: We aimed to evaluate the correlation between MKK4 expression and clinicopathological features, KRAS/NRAS mutation in colorectal cancer. Methods: MKK4 expression was assessed by immunoreactivity score (IRS). Staining intensity(SI) and percentage of positively stained cells (PP) were used for IRS (IRS = SI×PP). Cutoffs were explored with ROC analysis. Patients were grouped as WIR ('weak immunoreactive'; IRS:0–2) and SIR ('strong immunoreactive'; IRS: >3). Results: We enrolled 95 patients. 63.2% had metastasis. Median follow-up was 31.4 months. KRAS/NRAS mutation rate was 45.2%. Median values for OS, DFS, and PFS were as 31.6, 17.2, and 10.3 months. WIR group had longer OS ( p = 0.03). Recurrence rate was 36.8%. Median DFS was longer for recurrent patients in WIR group ( p = 0.055). KRAS or NRAS wild-type patients and those with left-sided tumors in WIR group had longer OS ( p = 0.029, p = 0.024, p = 0.03). There was no PFS difference ( p : 0.15). In correlation analysis, there was a negative correlation between MKK4 expression and KRAS mutation, NRAS mutation, OS, PFS, DFS ( r : –0, 06; r : –0, 02; r : –0, 10; r : –0, 06; r : –0, 34). Only the correlation for MKK4 expression and DFS was significant ( p = 0.04). Conclusion: MKK4 expression inversely correlates with survival outcomes. Patients with KRAS/NRAS wild-type, left-sided tumors with WIR had longer OS.
- Is Part Of:
- Expert review of molecular diagnostics. Volume 20:Number 8(2020)
- Journal:
- Expert review of molecular diagnostics
- Issue:
- Volume 20:Number 8(2020)
- Issue Display:
- Volume 20, Issue 8 (2020)
- Year:
- 2020
- Volume:
- 20
- Issue:
- 8
- Issue Sort Value:
- 2020-0020-0008-0000
- Page Start:
- 851
- Page End:
- 859
- Publication Date:
- 2020-08-02
- Subjects:
- Colorectal cancer -- MKK4 -- RAS mutation -- WIR -- SIR
Molecular diagnosis -- Periodicals
616.0758205 - Journal URLs:
- http://informahealthcare.com/toc/ero/current ↗
http://www.future-drugs.com/loi/erm ↗
http://www.tandfonline.com/toc/iero20/current ↗
http://informahealthcare.com ↗ - DOI:
- 10.1080/14737159.2020.1784728 ↗
- Languages:
- English
- ISSNs:
- 1473-7159
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 3842.002987
British Library DSC - BLDSS-3PM
British Library HMNTS - Digital store
British Library HMNTS - ELD Digital store - Ingest File:
- 22649.xml